Show simple item record

dc.contributor.authorWoods, BSen_US
dc.contributor.authorSideris, Een_US
dc.contributor.authorSydes, MRen_US
dc.contributor.authorGannon, MRen_US
dc.contributor.authorParmar, MKBen_US
dc.contributor.authorAlzouebi, Men_US
dc.contributor.authorAttard, Gen_US
dc.contributor.authorBirtle, AJen_US
dc.contributor.authorBrock, Sen_US
dc.contributor.authorCathomas, Ren_US
dc.contributor.authorChakraborti, PRen_US
dc.contributor.authorCook, Aen_US
dc.contributor.authorCross, WRen_US
dc.contributor.authorDearnaley, DPen_US
dc.contributor.authorGale, Jen_US
dc.contributor.authorGibbs, Sen_US
dc.contributor.authorGraham, JDen_US
dc.contributor.authorHughes, Ren_US
dc.contributor.authorJones, RJen_US
dc.contributor.authorLaing, Ren_US
dc.contributor.authorMason, MDen_US
dc.contributor.authorMatheson, Den_US
dc.contributor.authorMcLaren, DBen_US
dc.contributor.authorMillman, Ren_US
dc.contributor.authorO'Sullivan, JMen_US
dc.contributor.authorParikh, Oen_US
dc.contributor.authorParker, CCen_US
dc.contributor.authorPeedell, Cen_US
dc.contributor.authorProtheroe, Aen_US
dc.contributor.authorRitchie, AWSen_US
dc.contributor.authorRobinson, Aen_US
dc.contributor.authorRussell, JMen_US
dc.contributor.authorSimms, MSen_US
dc.contributor.authorSrihari, NNen_US
dc.contributor.authorSrinivasan, Ren_US
dc.contributor.authorStaffurth, JNen_US
dc.contributor.authorSundar, Sen_US
dc.contributor.authorThalmann, GNen_US
dc.contributor.authorTolan, Sen_US
dc.contributor.authorTran, ATHen_US
dc.contributor.authorTsang, Den_US
dc.contributor.authorWagstaff, Jen_US
dc.contributor.authorJames, NDen_US
dc.contributor.authorSculpher, MJen_US
dc.identifier.citationEuropean urology oncology, 2018, 1 (6), pp. 449 - 458en_US
dc.description.abstractBACKGROUND:Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with metastatic disease and prolongs failure-free survival for those without. To date there has been no formal assessment of whether funding docetaxel in this setting represents an appropriate use of UK National Health Service (NHS) resources. OBJECTIVE:To assess whether administering docetaxel to men with PC starting long-term hormone therapy is cost-effective in a UK setting. DESIGN, SETTING, AND PARTICIPANTS:We modelled health outcomes and costs in the UK NHS using data collected within the STAMPEDE trial, which enrolled men with high-risk, locally advanced metastatic or recurrent PC starting first-line hormone therapy. INTERVENTION:SOC was hormone therapy for ≥2 yr and radiotherapy in some patients. Docetaxel (75mg/m2) was administered alongside SOC for six three-weekly cycles. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS:The model generated lifetime predictions of costs, changes in survival duration, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). RESULTS AND LIMITATIONS:The model predicted that docetaxel would extend survival (discounted quality-adjusted survival) by 0.89 yr (0.51) for metastatic PC and 0.78 yr (0.39) for nonmetastatic PC, and would be cost-effective in metastatic PC (ICER £5514/QALY vs SOC) and nonmetastatic PC (higher QALYs, lower costs vs SOC). Docetaxel remained cost-effective in nonmetastatic PC when the assumption of no survival advantage was modelled. CONCLUSIONS:Docetaxel is cost-effective among patients with nonmetastatic and metastatic PC in a UK setting. Clinicians should consider whether the evidence is now sufficiently compelling to support docetaxel use in patients with nonmetastatic PC, as the opportunity to offer docetaxel at hormone therapy initiation will be missed for some patients by the time more mature survival data are available. PATIENT SUMMARY:Starting docetaxel chemotherapy alongside hormone therapy represents a good use of UK National Health Service resources for patients with prostate cancer that is high risk or has spread to other parts of the body.en_US
dc.format.extent449 - 458en_US
dc.subjectProstatic Neoplasmsen_US
dc.subjectNeoplasm Recurrence, Localen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectQuality-Adjusted Life Yearsen_US
dc.subjectMiddle Ageden_US
dc.subjectCost-Benefit Analysisen_US
dc.subjectStandard of Careen_US
dc.subjectUnited Kingdomen_US
dc.titleAddition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.en_US
dc.typeJournal Article
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEuropean urology oncologyen_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.embargo.termsNot knownen_US
icr.researchteamClinical Academic Radiotherapy (Dearnaley)en_US
dc.contributor.icrauthorParker, Chrisen_US
dc.contributor.icrauthorDearnaley, Daviden_US

Files in this item


This item appears in the following Collection(s)

Show simple item record
Except where otherwise noted, this item's license is described as